In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the ...

In fact, at AmerisourceBergen, we’re seeing health system customers actively engage us about biosimilars and how to integrate these products into their formularies and care plans. Expansion of ...

Witnesses at the April 8 hearing told legislators biosimilars save patients and taxpayers money, that pharmacy benefit ...

Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

This adds to BioDlink's portfolio of international GMP approvals, following recent certifications in Brazil, Indonesia, Egypt ...

OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing, aiming to strengthen global supply ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture ...

Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar ...

Alvotech (ALVO) stock is in focus as the company partners with Advanz Pharma to market three additional biosimilars across Europe. Read more here.

Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta biosimilar drug for MS.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.